John P. Cello, MD; James H. Grendell, MD; Paul Basuk, MD; Douglas Simon, MD; Louis Weiss, MD; Murray Wittner, MD; Richard P. Rood, MD; C. Mel Wilcox, MD; Chris E. Forsmark, MD; Alexandra E. Read, MD; Julie A. Satow, RN; Cynthia S. Weikel, MD; Cheryl Beaumont, RN
▪ Objective: To determine the efficacy and safety of octreotide for treatment of refractory, profuse diarrhea in patients with the acquired immunodeficiency syndrome (AIDS).
▪ Design: A prospective, open-label study.
▪ Setting: Inpatient metabolic units of four university medical centers.
▪ Patients: Fifty-one patients infected with human immunodeficiency virus (HIV) who had uncontrolled diarrhea (≥ 500-mL liquid stool per day) despite treatment with maximally tolerable doses of antidiarrheal medications.
▪ Intervention: After initial baseline studies, patients received octreotide, 50 µg every 8 hours for 48 hours. If stool volume was not reduced to < 250 mL/d, the dose of octreotide was increased stepwise to 100, 250, and 500 µg.
▪ Main Results: Fifty men and one woman (mean age, 36.3 ± 1.1 years) entered and completed the 28-day protocol (14 days of inpatient therapy and 14 days of outpatient therapy). Stool frequency and volume decreased significantly (6.5 ± 0.5 stools per day on day 0 compared with 3.8 ± 0.3 stools per day on day 21 [P < 0.001] and 1604 ± 180 mL/d on day 0 compared with 1084 ± 162 mL/d on day 14 [P < 0.001], respectively). Twenty-one patients (41.2%) were considered to be partial or complete responders (reduction in daily stool volume by ≥ 50% of initial collections or reduction to ≤ 250 mL/d). Of the 21 responders, 14 (67%) had no identifiable pathogens at initial screening compared with 9 of 30 (30%) nonresponders (P < 0.01).
▪ Conclusion: Patients with AIDS-associated refractory watery diarrhea, especially those without identifiable pathogens, may respond favorably to subcutaneously administered octreotide. This drug deserves further study in a randomized, placebo-controlled trial.
Cello JP, Grendell JH, Basuk P, et al. Effect of Octreotide on Refractory AIDS-associated Diarrhea: A Prospective, Multicenter Clinical Trial. Ann Intern Med. 1991;115:705–710. doi: https://doi.org/10.7326/0003-4819-115-9-705
Download citation file:
Published: Ann Intern Med. 1991;115(9):705-710.
Diarrhea, Gastroenterology/Hepatology, Infectious Disease.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use